Trial Profile
A randomized, double-blind, placebo-controlled efficacy and safety comparison of fixed-dose ranges of atomoxetine hydrochloride in child outpatients with attention-deficit/hyperactivity disorder [ADHD]
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Dec 2009
Price :
$35
*
At a glance
- Drugs Atomoxetine (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Therapeutic Use
- 16 Oct 2006 Status change
- 06 Sep 2006 Status change
- 07 Nov 2005 New trial record.